1.04
1.04 (0%)
As of Feb 14, 2025
Bone Biologics Corp [BBLG]
Source:
Company Overview
Bone Biologics Corp is a medical device company that is currently focused on bone regeneration in spinal fusion using the recombinant human proteinknown as NELL-1. NELL-1 in combination with DBM, demineralized bone matrix, is an osteopromotive recombinant protein that providestarget specific control over bone regeneration.
| Country | United States |
| Headquarters | burlington, massachusetts |
| Phone Number | (781) 552-4452 |
| Industry | manufacturing |
| CEO | Jeffrey Frelick |
| Website | www.bonebiologics.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-4.2 |
| Net Income | $-4.1 |
| Net Cash | $0.3 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -108.2% |
| Profit as % of Stockholder Equity | -118.1% |
Management Effectiveness
| Return on Equity | -118.1% |
| Return on Assets | -106.5% |
| Turnover Ratio | |
| EBITA | $-4.2 |
Balance Sheet and Cash Flow Measures
| Total Assets | $3.9 |
| Total Liabilities | $0.4 |
| Operating Cash Flow | $-4.1 |
| Investing Cash Flow | |
| Financing Cash Flow | $4.4 |
